Stablix is a technology company.
Stablix has raised $63.0M across 1 funding round.
Stablix has raised $63.0M in total across 1 funding round.
Stablix has raised $63.0M in total across 1 funding round.
Stablix's investors include Access Biotechnology, Tak Cheung, New Enterprise Associates, Polaris Partners, SR One, Vensana Capital, Versant Ventures.
Stablix is a biotechnology company founded in 2021, specializing in targeted deubiquitination therapeutics (TDT) and targeted protein stabilization (TPS). It develops heterobifunctional small molecules that recruit deubiquitinase enzymes to stabilize target proteins, addressing diseases caused by protein insufficiency, particularly in oncology and other unmet medical needs.[1][2][5] Based in New York City with operations in Boston, Stablix has raised $63M in Series A funding and employs 11-50 people, focusing on transformative small-molecule drugs for devastating diseases like gastrointestinal stromal tumors (GIST).[1][2] The company serves patients with conditions driven by protein degradation issues, solving the problem of unstable proteins through a novel modality inverse to PROTACs, with early momentum from partnerships like Vertex Pharmaceuticals.[3]
Stablix was founded in 2021 in New York, New York, as a creative, multidisciplinary team of scientists and leaders pioneering TDT.[1][2][4] Key leadership includes experienced executives like a former Executive Vice President of R&D at Biogen, CEO of ZymoGenetics (acquired by Bristol Myers Squibb), and leaders from Seattle Genetics, Amgen, and Immunex, bringing deep biotech expertise in drug development and acquisitions.[3] The idea emerged from recognizing protein stabilization as an underexplored "first-in-category" approach—roughly two years into development, Stablix announced a collaboration with Vertex Pharmaceuticals, granting Vertex exclusive rights to certain molecules and validating early traction in protein stabilization therapeutics.[3]
Stablix rides the wave of precision protein modulation, a hot trend in biotech shifting from degradation (PROTACs) to stabilization for hard-to-drug targets like those in resistant cancers.[1][3] Timing is ideal amid rising TKI resistance in oncology—e.g., GIST patients progressing on imatinib/sunitinib—and demand for small-molecule alternatives to biologics.[1] Market forces like biotech M&A (e.g., Seattle Genetics by Pfizer, Immunex by Amgen) and big pharma interest (Vertex deal) favor Stablix's platform, influencing the ecosystem by expanding the deubiquitination toolkit beyond traditional inhibition.[3] This positions it to shape next-gen therapies in neoplasms and immune disorders.[3]
Stablix is poised for clinical advancement, with Vertex collaboration accelerating molecule development into trials for GIST and beyond, potentially yielding first-in-class stabilizers.[3] Trends like AI-driven discovery (e.g., PatSnap tools) and regulatory focus on novel modalities will propel growth, evolving its influence from pioneer to ecosystem leader via partnerships and exits.[3] As protein stabilization matures, Stablix could redefine drugging undruggable targets, building on its strong funding and team to deliver transformative medicines.[1][2]
Stablix has raised $63.0M across 1 funding round. Most recently, it raised $63.0M Series A in June 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 1, 2021 | $63.0M Series A | Access Biotechnology, Tak Cheung, New Enterprise Associates, Polaris Partners, SR One, Vensana Capital, Versant Ventures |